Development of a model for benefit-risk assessment of medicines based on multi-criteria decision analysis
29-30th March 2004, London School of Economics (LSE), UK
The primary objective of the meeting was to develop a global perspective on risk management from both regulators and companies. It was also the intention to develop recommendations to ensure that the number of medicines available worldwide is maximised by:
- A discussion of the regulatory, risk management strategies used in companies during the development of new active substances and how these are changing.
- Reviewing benefit/risk decision making in agencies.
- Sharing experiences of risk management techniques during product development, identifying areas for improvement and good practice, by a review of recent case studies.